Post-Transplantation Lymphoproliferative Disorder After Kidney Transplantation: Report of a Nationwide French Registry and the Development of a New Prognostic Score
Authors:
- Sophie CaillardSophie Caillard
- Raphael PorcherRaphael Porcher
- François ProvotFPFrançois Provot
- Jacques DantalJDJacques Dantal
- Sylvain ChoquetSCSylvain Choquet
- Antoine DurrbachADAntoine Durrbach
- Emmanuel MorelonEMEmmanuel Morelon
- Valérie MoalVMValérie Moal
- Benedicte JanbonBJBenedicte Janbon
- Eric AlamartineEric Alamartine
- Claire Pouteil NobleCNClaire Pouteil Noble
- Delphine MorelDMDelphine Morel
- 1 April 2013
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 31 (10) , 1302-1309
Abstract
Purpose: Post-transplantation lymphoproliferative disorder (PTLD) is associated with significant mortality in kidney transplant recipients. We conducted a prospective survey of the occurrence of PTLD in a French nationwide population of adult kidney recipients over 10 years. Patients and Methods: A French registry was established to cover a nationwide population of transplant recipients and prospectively enroll all adult kidney recipients who developed PTLD between January 1, 1998, and December 31, 2007. Five hundred patient cases of PTLD were referred to the French registry. The prognostic factors for PTLD were investigated using Kaplan-Meier and Cox analyses. Results: Patients with PTLD had a 5-year survival rate of 53% and 10-year survival rate of 45%. Multivariable analyses revealed that age > 55 years, serum creatinine level > 133 μmol/L, elevated lactate dehydrogenase levels, disseminated lymphoma, brain localization, invasion of serous membranes, monomorphic PTLD, and T-cell PTLD were independent prognostic indicators of poor survival. Considering five variables at diagnosis (age, serum creatinine, lactate dehydrogenase, PTLD localization, and histology), we constructed a prognostic score that classified patients with PTLD as being at low, moderate, high, or very high risk for death. The 10-year survival rate was 85% for low-, 80% for moderate-, 56% for high-, and 0% for very high–risk recipients. Conclusion: This nationwide study highlights the prognostic factors for PTLD and enables the development of a new prognostic score. After validation in an independent cohort, the use of this score should allow treatment strategies to be better tailored to individual patients in the future.Keywords
This publication has 27 references indexed in Scilit:
- Rituximab in the management of post-transplantation lymphoproliferative disorder after solid organ transplantation: proceed with cautionAnnals of Hematology, 2007
- The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOPBlood, 2006
- Post-Transplant Lymphoproliferative Disorders Occurring After Renal Transplantation in Adults: Report of 230 Cases From the French RegistryAmerican Journal of Transplantation, 2006
- Lymphoproliferative Disease after Renal Transplantation in Australia and New ZealandTransplantation, 2005
- Analysis of Factors that Influence Survival with Post-Transplant Lymphoproliferative Disorder in Renal Transplant Recipients: The Israel Penn International Transplant Tumor Registry ExperienceAmerican Journal of Transplantation, 2005
- Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab eraLeukemia & Lymphoma, 2005
- Lymphomas After Solid Organ Transplantation: A Collaborative Transplant Study ReportAmerican Journal of Transplantation, 2004
- Lymphomas occurring late after solid-organ transplantationTransplantation, 2002
- Identification of Prognostic Factors in 61 Patients With Posttransplantation Lymphoproliferative DisordersJournal of Clinical Oncology, 2001
- A Predictive Model for Aggressive Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993